国际妇产科学杂志2017，Vol.44Issue(6)：677-680,694,5.
Olaparib靶向治疗晚期卵巢癌的研究进展
Researoh Progress of Olaparib as Targeted Therapeutics for Advanced Ovarian Cancer
摘要
Abstract
The patients with advanced ovarian cancer have poor prognosis. The high mortality for patients with advanced ovarian cancer is attributable to the shortage of efficient therapeutic strategies. Poly ADP-ribose polymerase (PARP) inhibitor is a novel type of antineoplastic targeting agent, which can cause BRCA-mutated cancer cells cannot repair the damaged DNA and result in cells death by"synthetic lethality"mechanism. Olaparib is one of the most widely studied PARP inhibitors, which is approved in the European Union and United States for the maintenance treatment of advanced, recurrent ovarian cancer associated with BRCA mutation and platinum sensitivity. Recent clinical trials have demonstrated the effective antineoplastic activity of olaparib as single agents and in combination with cytotoxic chemotherapy and molecular targeted agents, showing an increase of progression free survival (PFS) and well tolerability, exhibiting a promising application prospects. The review discusses the mechanism, clinical trials and adverse effects of olaparib in advanced ovarian tumor treatment .关键词
卵巢肿瘤/基因,BRCA1/基因,BRCA2/合成致死Key words
Ovarian neoplasms/Genes,BRCA1/Genes,BRCA2/Synthetic lethality引用本文复制引用
钟姗姗,狄文..Olaparib靶向治疗晚期卵巢癌的研究进展[J].国际妇产科学杂志,2017,44(6):677-680,694,5.基金项目
国家自然科学基金(81472426) （81472426）
第四轮公共卫生三年行动计划重点学科建设(15GWZK0701) （15GWZK0701）
上海市重中之重临床医学中心项目(2017ZZ02016) （2017ZZ02016）
